Using RNA to enhance immune responses for cancer treatment and vaccines
Programmable 'all-in-one' RNA as a molecular scaffold for targeted combinatorial innate immune activation
['FUNDING_R21'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11005287
This study is exploring a new way to boost the body's natural defenses against cancer and infections by using a special RNA tool that helps the immune system respond better to treatments, making it more effective for patients.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11005287 on ClinicalTrials.gov |
What this research studies
This research aims to develop a novel RNA-based platform that can activate the innate immune system to improve responses to cancer immunotherapies and infectious disease vaccines. By engineering a modular 'all-in-one' RNA scaffold, the project seeks to combine multiple immune-activating signals in a way that mimics natural pathogen recognition. This approach addresses current limitations in existing therapies by allowing for precise tuning of immune responses, potentially leading to more effective treatments for patients. The research will involve laboratory experiments to test the effectiveness of these RNA constructs in stimulating immune cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer or those needing improved vaccine responses against infectious diseases.
Not a fit: Patients who are not suffering from cancer or infectious diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments and vaccines that provide better immune responses for patients.
How similar studies have performed: Previous research has shown promise in using combinatorial approaches to activate the immune system, suggesting potential success for this novel RNA-based method.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WU, CONNIE — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: WU, CONNIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy